TransCode Therapeutics Reports Data From First-in-Human Clinical Study Using TTX-MC138
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics has reported data from its first-in-human clinical study using TTX-MC138, a treatment targeting microRNA-10b for metastatic cancer. The study showed promising results in terms of safety and potential efficacy.
May 29, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TransCode Therapeutics (RNAZ) has reported promising data from its first-in-human clinical study using TTX-MC138, targeting microRNA-10b for metastatic cancer. The study indicates potential efficacy and safety, which could positively impact the stock price.
The positive data from the clinical study suggests that TTX-MC138 could be an effective treatment for metastatic cancer, which is a significant milestone for TransCode Therapeutics. This news is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100